Abstract
In radiotherapy the normal tissue reaction is often a limiting factor for radiation treatment. Still there is no screening method, which predicts normal tissue reaction on radiotherapy, especially in comparison to tumor tissue, and therefore allows tailoring of the radiation dose to each patient. Here, we present a case of severe radiation-related side effects. We applied classical cytogenetic techniques (Giemsa-banding and staining of centromeric regions), the comet assay as well as multicolor fluorescence in situ hybridization on peripheral blood lymphocytes of this patient in order to determine the radio-sensitivity on the DNA level and to correlate these findings with the clinical outcome. Our investigations revealed abnormalities on chromosome 9, deficiencies in the DNA-repair capacity after radiation exposure and a high number of radiation induced chromosomal aberrations. A detected high amount of residual damage two or three hours after radiation exposure and repair as well as the high number of chromosomal aberrations (ChAs) suggests a correlation between repair capacity and radiation induced ChAs. We concluded that the detected abnormalities might serve as a genetic basis for the radio-sensitive phenotype of this patient. Taken together this report strengthens the idea that intensive DNA genomic analysis of individual patients can serve as the basis for more favourable treatment of cancer patients.
Keywords: Radiation therapy, DNA damage and repair, Double strand breaks, Comet assay, Radiation induced chromosomal aberrations, M-FISH, radio-sensitivity, situ hybridization, Giemsa-Trypsin-Giemsa, centromere
Current Genomics
Title:Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Volume: 13 Issue: 6
Author(s): K.M. Greulich-Bode, F. Zimmermann, W.-U. Muller, B. Pakisch, M. Molls and F. Wurschmidt
Affiliation:
Keywords: Radiation therapy, DNA damage and repair, Double strand breaks, Comet assay, Radiation induced chromosomal aberrations, M-FISH, radio-sensitivity, situ hybridization, Giemsa-Trypsin-Giemsa, centromere
Abstract: In radiotherapy the normal tissue reaction is often a limiting factor for radiation treatment. Still there is no screening method, which predicts normal tissue reaction on radiotherapy, especially in comparison to tumor tissue, and therefore allows tailoring of the radiation dose to each patient. Here, we present a case of severe radiation-related side effects. We applied classical cytogenetic techniques (Giemsa-banding and staining of centromeric regions), the comet assay as well as multicolor fluorescence in situ hybridization on peripheral blood lymphocytes of this patient in order to determine the radio-sensitivity on the DNA level and to correlate these findings with the clinical outcome. Our investigations revealed abnormalities on chromosome 9, deficiencies in the DNA-repair capacity after radiation exposure and a high number of radiation induced chromosomal aberrations. A detected high amount of residual damage two or three hours after radiation exposure and repair as well as the high number of chromosomal aberrations (ChAs) suggests a correlation between repair capacity and radiation induced ChAs. We concluded that the detected abnormalities might serve as a genetic basis for the radio-sensitive phenotype of this patient. Taken together this report strengthens the idea that intensive DNA genomic analysis of individual patients can serve as the basis for more favourable treatment of cancer patients.
Export Options
About this article
Cite this article as:
Greulich-Bode K.M., Zimmermann F., Muller W.-U., Pakisch B., Molls M. and Wurschmidt F., Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity, Current Genomics 2012; 13 (6) . https://dx.doi.org/10.2174/138920212802510475
DOI https://dx.doi.org/10.2174/138920212802510475 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Overview of Dietary Influences on Atherosclerotic Vascular Disease:Epidemiology and Prevention
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Features for Heartbeat Sound Signal Normal and Pathological
Recent Patents on Computer Science Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives
Current Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Current Problems, New Opportunities and Future Directions of Antiplatelet Therapy - Increasing Role of Novel Antiplatelet Agents in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Current Vascular Pharmacology Heart Failure in the Middle East
Current Cardiology Reviews Lipid Profile of Pig Tissues Contrasting in Meat Production
The Natural Products Journal The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine